Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant

摘要: Survival rates for pediatric cancer have steadily improved over time but it remains a significant cause of morbidity and mortality among children. Infections are major complication its treatment. Community acquired respiratory viral infections (CRV) in these patients increase morbidity, can lead to delay chemotherapy. These the result with heterogeneous group viruses including RNA viruses, such as syncytial virus (RSV), influenza (IV), parainfluenza (PIV), metapneumovirus (HMPV), rhinovirus (RhV), coronavirus (CoV). maintain similar seasonal pattern those immunocompetent patients. Clinical manifestations vary significantly depending on type degree immunosuppression, ranging from asymptomatic or mild disease rapidly progressive fatal pneumonia this population characterized by high rate progression upper lower tract infection prolonged shedding. Use corticosteroids immunosuppressive therapy risk factors severe disease. The clinical course is often difficult predict, signs unreliable. Accurate prognostic immune markers, which become part standard care systemic infections, currently lacking; management CRV controversial. Defining effective prophylactic therapeutic strategies challenging, especially considering, spectrum immunocompromised patients, variety presence other opportunistic medical problems. Prevention one most important against viruses. Early diagnosis, supportive antivirals at an early stage, when available indicated, proven beneficial. However, exception neuraminidase inhibitors infection, there no accepted treatments. In high-risk pre-emptive treatment (URTI) decrease LRTI common strategy. future, load markers may prove beneficial predicting disease, supporting decision making monitor population.